The present disclosure relates to in vivo methods for producing anti-idiotypic antibodies. In some aspects, anti-idiotypic antibodies are generated by co-administering to a mouse a first antibody having a murine IgG2a isotype and a second antibody that targets mouse B cells and has a murine IgG2a isotype. In some embodiments, the mouse expresses the Igh-1.sup.b allele of IgG2a, and the second antibody binds a mouse B cell surface marker selected from the group consisting of CD19, CD20, CD21, CD22, CD40, CD45, IgM, and IgD.

The present invention relates to amino acid sequences that are directed against IL-23. The amino acid sequences of the present invention comprise two Nanobodies against IL-23 and one Nanobody against serum albumin, linked by two linkers (9GS linkers). In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as anti-IL 23 polypeptides of the invention).

Provided are monoclonal antibodies that detect CD19 CAR-modified immune cells and CAR-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of CAR-modified immune cells.

Monoclonal antibodies produced in plants at high levels wherein elimination of L chain glycans improves plasma stability of certain plant derived bnAbs are provided. Monoclonal antibodies produced in plants which exhibit no or reduced immunogenicity after multiple injections are provided. Methods of production of the foregoing are provided. Methods of determining immunogenicity assessing the immunogenicity and neutralizing ability of the same are provided. Methods of treating HIV using monoclonal antibodies produced in plants are also provided.

Subject matter of the present invention is an Antibody or antibody fragment or non-Ig scaffold binding to a binding region of an anti-NMDAR1 antibody and its uses in therapy or diagnosis.

Disclosed herein are compositions comprising recombinant arenavirus monoclonal antibodies and antigen-binding fragments thereof, as well as therapeutic methods using the antibodies. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains.

Disclosed herein is a method for producing a recombinant polypeptide in a mammalian cell culture in which the mammalian cells have a modified microRNA activity level. In one embodiment, a microRNA activity level is increased. In another embodiment, a microRNA activity level is decreased. In a more particular embodiment, the mammalian cells have a reduced miRNA-let-7a activity level.

Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.

The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.

The present invention is concerned with antigen binding polypeptides, and in particular conventional antibodies derived from camelid species, that specifically bind to target antigens that are either self-antigens or highly conserved antigens. The present invention also relates to anti-idiotype antigen binding peptides which bind to a target antigen comprising the variable region of an antibody obtained from a species within the family Camelidae.